Section
Keytruda
The latest Keytruda coverage from Bullquill: sourced, dated and explained.
1 POSTSUPDATED
IndexDate · Title · Reading time
No articles in this language here yet. Showing English.
-
Moderna melanoma vaccine data surface early; shares fall 17.6%
The Phase 3 INTerpath-001 results were positive, but the 42% reduction came in below the 49% seen in the earlier Phase 2b study, though the trials are not directly comparable. Full data are due at ESMO in Madrid on 24 October.
